Strategies towards Improving the Pharmacokinetic Profile of ε-Substituted Lysinol-Derived HIV Protease Inhibitors

ChemMedChem

Volumn 6, Issue 2, 2011, Pages 253-257

  Rajapakse, Hemaka A ^a   Walji, Abbas M ^a   Moore, Keith P ^a   Zhu, Hong ^a   Mitra, Aurpon W ^a   Gregro, Alison R ^a   Tinney, Elizabeth ^a   Burlein, Christine ^a   Touch, Sinoeun ^a   Paton, Brenda L ^a   Carroll, Steven S ^a   DiStefano, Daniel J ^a   Lai, Ming Tain ^a   Grobler, Jay A ^a   Sanchez, Rosa I ^a   Williams, Theresa M ^a   Vacca, Joseph P ^a   Nantermet, Philippe G ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

substituted lysines; HIV; Inhibitors; Pharmacokinetics; Proteases

Indexed keywords

ANILINE DERIVATIVE; BENZYL ALCOHOL DERIVATIVE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LYSINE DERIVATIVE; LYSINOL DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DEPROTECTION REACTION; DOG; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG POTENCY; DRUG SYNTHESIS; FEASIBILITY STUDY; GENE MUTATION; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; LYSINE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79251588434     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.201000395     Document Type: Article

References (16)

1. F. J. Palella Jr., D. K. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, D. J. Aschman, S. D. N. Holmberg, N. Engl. J. Med. 1998, 338, 853-860.
2. For a recent review on HIV Protease inhibitors see: A. M. J. Wensing, N. M. vanMaarseveen, M. Nijhuis, Antiviral Res. 2010, 85, 59-74.
3. B. R. Stranix, J.-F. Lavallée, G. Sévigny, J. Yelle, V. Perron, N. LeBerre, D. Herbart, J. J. Wu, Bioorg. Med. Chem. Lett. 2006, 16, 3459-3462.
4. G. Sévigny, B. Stranix, B. Tian, A. Dubois, G. Sauvé C. Petropoulos, Y. Lie, N. Hellmann, B. Conway, J. Yelle, Antiviral Res. 2006, 70, 17-20.
5. S. Dandache, C. A. Coburn, M. Oliveira, T. J. Allison, M. K. Holloway, J. J. Wu, B. R. Stranix, C. Panchal, M. A. Wainberg, J. P. Vacca, J. Med. Virol. 2008, 80, 2053-2063.
6. K. L. G. Jones, M. K. Holloway, H.-P. Su, S. S. Carroll, C. Burlein, S. Touch, D. J. DiStefano, R. I. Sanchez, T. M. Williams, J. P. Vacca, C. A. Coburn, Bioorg. Med. Chem. Lett. 2010, 20, 4065-4068.
7. 95) is defined as the concentration of agent that inhibits the spread of HIV-1 infection in susceptible cell culture by 95%. MT4 human T-lymphoid cells were maintained in RPMI-1640 medium containing 10% heat-inactivated fetal bovine serum. Cells were infected all together at low multiplicity (0.01) using HIV-1 strain IIIb and were incubated for 24h. At this time, cells were washed and distributed into 96-well microtiter dishes. Serial twofold dilutions of inhibitor were added to the wells, and the cultures were maintained for three additional days. Virus spread was assessed by HIV-1 P24 core antigen ELISA. Control cultures in the absence of inhibitor were fully infected after four days.
8. For the discovery of benzyl alcohols see the following patent: J. W. Erickson, S. V. Gulnik, A. K. Ghosh, K. A. Hussain, (National Institutes of Health; Rockville, USA; University of Illinois, Urbana, USA), WO/1999/067254, 1999.
9. 3 via an open transition state, the (R)-isomer of the chiral auxiliary was used; for details see: G. K. Prakash, M. Mandal, J. Am. Chem. Soc. 2002, 124, 6538-6539.
10. A fluorescence resonance energy transfer (FRET)-based assay using HIV protease substrate Ser-Gln-Asn-(β-naphthylalanine)-Pro-Ile-Val.
11. Handbook of Metathesis, (Ed.: R.H. Grubbs), Wiley-VCH, Weinheim, 2003.
12. The diastereomers were separable by silica gel chromatography at stepj in Scheme2 or by preparative HPLC at stepl in Scheme2.
13. G. K. Prakash, M. Mandal, G. A. Olah, Org. Lett. 2001, 3, 2847-2850.
14. G. H. Posner, C.-Y. Cho, J. V. Green, Y. Zhang, P. Talalay, J. Med. Chem. 1994, 37, 170-176.
15. J. Tanuwidjaja, H. M. Peltier, J. A. Ellman, J. Org. Chem. 2007, 72, 626-629.
16. For comparison, the in vitro potency of darunavir (DRV) in our 10% and 50% serum-shifted SPREAD assays are 9 and 23nm, respectively.